We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Marina Biotech Announces Patent Allowance for its Proprietary Nucleic Acid Delivery Technology
Product News

Marina Biotech Announces Patent Allowance for its Proprietary Nucleic Acid Delivery Technology

Marina Biotech Announces Patent Allowance for its Proprietary Nucleic Acid Delivery Technology
Product News

Marina Biotech Announces Patent Allowance for its Proprietary Nucleic Acid Delivery Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Marina Biotech Announces Patent Allowance for its Proprietary Nucleic Acid Delivery Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Marina Biotech, Inc. has announced that the Canadian Patent Office has issued a Notice of Allowance for patent application 2,438,116 with claims that broadly cover amphoteric liposomal formulations (SMARTICLES®) and their use for the delivery of nucleic acids and other compounds with therapeutic application.

This allowance adds to the company's existing global patent estate for SMARTICLES delivery technology, which includes over 40 issued patents in countries including the United States, Japan, China, Singapore, Australia and countries throughout Europe.

At present, ProNAi Therapeutics Inc., a privately held biopharmaceutical company and licensee of the SMARTICLES technology, is conducting a dose-escalating Phase 1 clinical study with a novel cancer therapeutic candidate (PNT2258) formulated with Marina Biotech's patented SMARTICLES delivery technology.

The primary objective of this study is to assess the safety and tolerability of PNT2258 in patients with advanced solid tumors, and to enable dose selection for subsequent efficacy studies in patients. A secondary objective of this study is pharmacokinetics. Thus far, ProNAi has enrolled six patients and completed dosing regimens on five of those patients.

"We are pleased that the Canadian patent office allowed these claims which cover and protect our SMARTICLES technology," stated J. Michael French, President and CEO at Marina Biotech.

French continued, "The Company's global intellectual property portfolio represents fundamental IP necessary to develop and commercialize multiple RNA-based therapies. ProNAi's efforts demonstrate the breadth of that IP estate with the application of our delivery technology to their proprietary and innovative DNAi-based oligonucleotide molecule.

Through ProNAi's efforts and capabilities, we expect to see significant SMARTICLES delivery technology advancements in the fight to treat cancer patients who have few, if any, therapeutic alternatives. In addition, we have ongoing collaborative efforts which are, in part, focused on both local and systemic delivery of siRNAs and other oligonucleotides using the SMARTICLES technology; one of multiple therapeutic options in the Marina Biotech nucleic acid-based discovery platform."

Advertisement